CN117964557A - 一种瑞司美替罗中间体的制备方法 - Google Patents
一种瑞司美替罗中间体的制备方法 Download PDFInfo
- Publication number
- CN117964557A CN117964557A CN202410111330.1A CN202410111330A CN117964557A CN 117964557 A CN117964557 A CN 117964557A CN 202410111330 A CN202410111330 A CN 202410111330A CN 117964557 A CN117964557 A CN 117964557A
- Authority
- CN
- China
- Prior art keywords
- compound
- preparation
- sodium
- reaction
- reaction solvent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 16
- BPRHUIZQVSMCRT-VEUZHWNKSA-N rosuvastatin Chemical compound CC(C)C1=NC(N(C)S(C)(=O)=O)=NC(C=2C=CC(F)=CC=2)=C1\C=C\[C@@H](O)C[C@@H](O)CC(O)=O BPRHUIZQVSMCRT-VEUZHWNKSA-N 0.000 title claims description 3
- 229960000672 rosuvastatin Drugs 0.000 title claims description 3
- 150000001875 compounds Chemical class 0.000 claims abstract description 25
- 238000000034 method Methods 0.000 claims abstract description 23
- 229940125782 compound 2 Drugs 0.000 claims abstract description 13
- 229940126214 compound 3 Drugs 0.000 claims abstract description 13
- OPFJDXRVMFKJJO-ZHHKINOHSA-N N-{[3-(2-benzamido-4-methyl-1,3-thiazol-5-yl)-pyrazol-5-yl]carbonyl}-G-dR-G-dD-dD-dD-NH2 Chemical compound S1C(C=2NN=C(C=2)C(=O)NCC(=O)N[C@H](CCCN=C(N)N)C(=O)NCC(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(O)=O)C(N)=O)=C(C)N=C1NC(=O)C1=CC=CC=C1 OPFJDXRVMFKJJO-ZHHKINOHSA-N 0.000 claims abstract description 12
- 229940126086 compound 21 Drugs 0.000 claims abstract description 12
- 238000006243 chemical reaction Methods 0.000 claims abstract description 11
- WWTBZEKOSBFBEM-SPWPXUSOSA-N (2s)-2-[[2-benzyl-3-[hydroxy-[(1r)-2-phenyl-1-(phenylmethoxycarbonylamino)ethyl]phosphoryl]propanoyl]amino]-3-(1h-indol-3-yl)propanoic acid Chemical compound N([C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)O)C(=O)C(CP(O)(=O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1C=CC=CC=1)CC1=CC=CC=C1 WWTBZEKOSBFBEM-SPWPXUSOSA-N 0.000 claims abstract description 10
- 229940126208 compound 22 Drugs 0.000 claims abstract description 10
- KGNDCEVUMONOKF-UGPLYTSKSA-N benzyl n-[(2r)-1-[(2s,4r)-2-[[(2s)-6-amino-1-(1,3-benzoxazol-2-yl)-1,1-dihydroxyhexan-2-yl]carbamoyl]-4-[(4-methylphenyl)methoxy]pyrrolidin-1-yl]-1-oxo-4-phenylbutan-2-yl]carbamate Chemical compound C1=CC(C)=CC=C1CO[C@H]1CN(C(=O)[C@@H](CCC=2C=CC=CC=2)NC(=O)OCC=2C=CC=CC=2)[C@H](C(=O)N[C@@H](CCCCN)C(O)(O)C=2OC3=CC=CC=C3N=2)C1 KGNDCEVUMONOKF-UGPLYTSKSA-N 0.000 claims abstract description 4
- 229940125833 compound 23 Drugs 0.000 claims abstract description 4
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 24
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 24
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 21
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 18
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 claims description 18
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 claims description 14
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 12
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 12
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims description 10
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 10
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 claims description 9
- 239000007810 chemical reaction solvent Substances 0.000 claims description 9
- 239000012279 sodium borohydride Substances 0.000 claims description 7
- 229910000033 sodium borohydride Inorganic materials 0.000 claims description 7
- JWUJQDFVADABEY-UHFFFAOYSA-N 2-methyltetrahydrofuran Chemical compound CC1CCCO1 JWUJQDFVADABEY-UHFFFAOYSA-N 0.000 claims description 6
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 6
- 238000010511 deprotection reaction Methods 0.000 claims description 6
- RBTARNINKXHZNM-UHFFFAOYSA-K iron trichloride Chemical compound Cl[Fe](Cl)Cl RBTARNINKXHZNM-UHFFFAOYSA-K 0.000 claims description 6
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 6
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 claims description 5
- 239000003153 chemical reaction reagent Substances 0.000 claims description 5
- 239000003638 chemical reducing agent Substances 0.000 claims description 5
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 claims description 4
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 4
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 claims description 4
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 claims description 4
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 claims description 4
- MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 claims description 4
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 claims description 4
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 claims description 4
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 claims description 4
- 150000007514 bases Chemical class 0.000 claims description 4
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 claims description 4
- 229910000024 caesium carbonate Inorganic materials 0.000 claims description 4
- XMPZTFVPEKAKFH-UHFFFAOYSA-P ceric ammonium nitrate Chemical compound [NH4+].[NH4+].[Ce+4].[O-][N+]([O-])=O.[O-][N+]([O-])=O.[O-][N+]([O-])=O.[O-][N+]([O-])=O.[O-][N+]([O-])=O.[O-][N+]([O-])=O XMPZTFVPEKAKFH-UHFFFAOYSA-P 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 4
- MFRIHAYPQRLWNB-UHFFFAOYSA-N sodium tert-butoxide Chemical compound [Na+].CC(C)(C)[O-] MFRIHAYPQRLWNB-UHFFFAOYSA-N 0.000 claims description 4
- CIHOLLKRGTVIJN-UHFFFAOYSA-N tert‐butyl hydroperoxide Chemical compound CC(C)(C)OO CIHOLLKRGTVIJN-UHFFFAOYSA-N 0.000 claims description 4
- 239000006096 absorbing agent Substances 0.000 claims description 3
- MFGOFGRYDNHJTA-UHFFFAOYSA-N 2-amino-1-(2-fluorophenyl)ethanol Chemical compound NCC(O)C1=CC=CC=C1F MFGOFGRYDNHJTA-UHFFFAOYSA-N 0.000 claims description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims description 2
- GQGBEYZHFLTHNX-UHFFFAOYSA-N N#CC(C(C=CC1=O)=O)=C1C#N.Cl.Cl Chemical compound N#CC(C(C=CC1=O)=O)=C1C#N.Cl.Cl GQGBEYZHFLTHNX-UHFFFAOYSA-N 0.000 claims description 2
- HUCVOHYBFXVBRW-UHFFFAOYSA-M caesium hydroxide Inorganic materials [OH-].[Cs+] HUCVOHYBFXVBRW-UHFFFAOYSA-M 0.000 claims description 2
- 238000006482 condensation reaction Methods 0.000 claims description 2
- JMMWKPVZQRWMSS-UHFFFAOYSA-N isopropanol acetate Natural products CC(C)OC(C)=O JMMWKPVZQRWMSS-UHFFFAOYSA-N 0.000 claims description 2
- 229940011051 isopropyl acetate Drugs 0.000 claims description 2
- GWYFCOCPABKNJV-UHFFFAOYSA-N isovaleric acid Chemical compound CC(C)CC(O)=O GWYFCOCPABKNJV-UHFFFAOYSA-N 0.000 claims description 2
- YNESATAKKCNGOF-UHFFFAOYSA-N lithium bis(trimethylsilyl)amide Chemical compound [Li+].C[Si](C)(C)[N-][Si](C)(C)C YNESATAKKCNGOF-UHFFFAOYSA-N 0.000 claims description 2
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 claims description 2
- BEOOHQFXGBMRKU-UHFFFAOYSA-N sodium cyanoborohydride Chemical compound [Na+].[B-]C#N BEOOHQFXGBMRKU-UHFFFAOYSA-N 0.000 claims description 2
- 239000007858 starting material Substances 0.000 abstract description 7
- 238000009776 industrial production Methods 0.000 abstract description 3
- XSVMFMHYUFZWBK-NSHDSACASA-N Rivastigmine Chemical compound CCN(C)C(=O)OC1=CC=CC([C@H](C)N(C)C)=C1 XSVMFMHYUFZWBK-NSHDSACASA-N 0.000 abstract 2
- 229960004136 rivastigmine Drugs 0.000 abstract 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 9
- -1 isopropenyl Grignard reagent Chemical class 0.000 description 8
- 238000000746 purification Methods 0.000 description 8
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 7
- 238000004128 high performance liquid chromatography Methods 0.000 description 7
- 239000008213 purified water Substances 0.000 description 7
- 230000015572 biosynthetic process Effects 0.000 description 6
- 238000004440 column chromatography Methods 0.000 description 6
- 229940125898 compound 5 Drugs 0.000 description 6
- 238000010168 coupling process Methods 0.000 description 6
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 description 6
- 239000012074 organic phase Substances 0.000 description 6
- 238000005859 coupling reaction Methods 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 238000003786 synthesis reaction Methods 0.000 description 5
- QFLWZFQWSBQYPS-AWRAUJHKSA-N (3S)-3-[[(2S)-2-[[(2S)-2-[5-[(3aS,6aR)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoylamino]-3-methylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-[1-bis(4-chlorophenoxy)phosphorylbutylamino]-4-oxobutanoic acid Chemical compound CCCC(NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)CCCCC1SC[C@@H]2NC(=O)N[C@H]12)C(C)C)P(=O)(Oc1ccc(Cl)cc1)Oc1ccc(Cl)cc1 QFLWZFQWSBQYPS-AWRAUJHKSA-N 0.000 description 4
- JRZDBBCBIQEJLA-UHFFFAOYSA-N 3,6-dichloro-4-propan-2-ylpyridazine Chemical compound CC(C)C1=CC(Cl)=NN=C1Cl JRZDBBCBIQEJLA-UHFFFAOYSA-N 0.000 description 4
- KGEXISHTCZHGFT-UHFFFAOYSA-N 4-azaniumyl-2,6-dichlorophenolate Chemical compound NC1=CC(Cl)=C(O)C(Cl)=C1 KGEXISHTCZHGFT-UHFFFAOYSA-N 0.000 description 4
- 239000007818 Grignard reagent Substances 0.000 description 4
- 230000008878 coupling Effects 0.000 description 4
- 238000001914 filtration Methods 0.000 description 4
- 239000012535 impurity Substances 0.000 description 4
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 3
- 238000005160 1H NMR spectroscopy Methods 0.000 description 3
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 3
- 239000012043 crude product Substances 0.000 description 3
- 239000000706 filtrate Substances 0.000 description 3
- 230000007062 hydrolysis Effects 0.000 description 3
- 238000006460 hydrolysis reaction Methods 0.000 description 3
- 239000001632 sodium acetate Substances 0.000 description 3
- 235000017281 sodium acetate Nutrition 0.000 description 3
- 238000001308 synthesis method Methods 0.000 description 3
- AOSZTAHDEDLTLQ-AZKQZHLXSA-N (1S,2S,4R,8S,9S,11S,12R,13S,19S)-6-[(3-chlorophenyl)methyl]-12,19-difluoro-11-hydroxy-8-(2-hydroxyacetyl)-9,13-dimethyl-6-azapentacyclo[10.8.0.02,9.04,8.013,18]icosa-14,17-dien-16-one Chemical compound C([C@@H]1C[C@H]2[C@H]3[C@]([C@]4(C=CC(=O)C=C4[C@@H](F)C3)C)(F)[C@@H](O)C[C@@]2([C@@]1(C1)C(=O)CO)C)N1CC1=CC=CC(Cl)=C1 AOSZTAHDEDLTLQ-AZKQZHLXSA-N 0.000 description 2
- GLGNXYJARSMNGJ-VKTIVEEGSA-N (1s,2s,3r,4r)-3-[[5-chloro-2-[(1-ethyl-6-methoxy-2-oxo-4,5-dihydro-3h-1-benzazepin-7-yl)amino]pyrimidin-4-yl]amino]bicyclo[2.2.1]hept-5-ene-2-carboxamide Chemical compound CCN1C(=O)CCCC2=C(OC)C(NC=3N=C(C(=CN=3)Cl)N[C@H]3[C@H]([C@@]4([H])C[C@@]3(C=C4)[H])C(N)=O)=CC=C21 GLGNXYJARSMNGJ-VKTIVEEGSA-N 0.000 description 2
- IWZSHWBGHQBIML-ZGGLMWTQSA-N (3S,8S,10R,13S,14S,17S)-17-isoquinolin-7-yl-N,N,10,13-tetramethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-amine Chemical compound CN(C)[C@H]1CC[C@]2(C)C3CC[C@@]4(C)[C@@H](CC[C@@H]4c4ccc5ccncc5c4)[C@@H]3CC=C2C1 IWZSHWBGHQBIML-ZGGLMWTQSA-N 0.000 description 2
- GUSWJGOYDXFJSI-UHFFFAOYSA-N 3,6-dichloropyridazine Chemical compound ClC1=CC=C(Cl)N=N1 GUSWJGOYDXFJSI-UHFFFAOYSA-N 0.000 description 2
- 229940126657 Compound 17 Drugs 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical class [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 2
- 102100033451 Thyroid hormone receptor beta Human genes 0.000 description 2
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Chemical compound BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 229940125773 compound 10 Drugs 0.000 description 2
- 229940125758 compound 15 Drugs 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 150000004795 grignard reagents Chemical class 0.000 description 2
- ZLVXBBHTMQJRSX-VMGNSXQWSA-N jdtic Chemical compound C1([C@]2(C)CCN(C[C@@H]2C)C[C@H](C(C)C)NC(=O)[C@@H]2NCC3=CC(O)=CC=C3C2)=CC=CC(O)=C1 ZLVXBBHTMQJRSX-VMGNSXQWSA-N 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 2
- ZRSNZINYAWTAHE-UHFFFAOYSA-N p-methoxybenzaldehyde Chemical compound COC1=CC=C(C=O)C=C1 ZRSNZINYAWTAHE-UHFFFAOYSA-N 0.000 description 2
- FDBYIYFVSAHJLY-UHFFFAOYSA-N resmetirom Chemical compound N1C(=O)C(C(C)C)=CC(OC=2C(=CC(=CC=2Cl)N2C(NC(=O)C(C#N)=N2)=O)Cl)=N1 FDBYIYFVSAHJLY-UHFFFAOYSA-N 0.000 description 2
- LPXPTNMVRIOKMN-UHFFFAOYSA-M sodium nitrite Chemical compound [Na+].[O-]N=O LPXPTNMVRIOKMN-UHFFFAOYSA-M 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 108091008762 thyroid hormone receptors ß Proteins 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- NWZSZGALRFJKBT-KNIFDHDWSA-N (2s)-2,6-diaminohexanoic acid;(2s)-2-hydroxybutanedioic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O.NCCCC[C@H](N)C(O)=O NWZSZGALRFJKBT-KNIFDHDWSA-N 0.000 description 1
- QSWLSAYLEATCSH-UHFFFAOYSA-N 3-propan-2-ylfuran-2,5-dione Chemical compound CC(C)C1=CC(=O)OC1=O QSWLSAYLEATCSH-UHFFFAOYSA-N 0.000 description 1
- SNBJJRQDOILAAT-UHFFFAOYSA-N 4-propan-2-yl-1,2-dihydropyridazine-3,6-dione Chemical compound CC(C)C1=CC(O)=NNC1=O SNBJJRQDOILAAT-UHFFFAOYSA-N 0.000 description 1
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical class [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 1
- 229910021595 Copper(I) iodide Inorganic materials 0.000 description 1
- 229910021578 Iron(III) chloride Inorganic materials 0.000 description 1
- LNUFLCYMSVYYNW-ZPJMAFJPSA-N [(2r,3r,4s,5r,6r)-2-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[[(3s,5s,8r,9s,10s,13r,14s,17r)-10,13-dimethyl-17-[(2r)-6-methylheptan-2-yl]-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-3-yl]oxy]-4,5-disulfo Chemical compound O([C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1C[C@@H]2CC[C@H]3[C@@H]4CC[C@@H]([C@]4(CC[C@@H]3[C@@]2(C)CC1)C)[C@H](C)CCCC(C)C)[C@H]1O[C@H](COS(O)(=O)=O)[C@@H](OS(O)(=O)=O)[C@H](OS(O)(=O)=O)[C@H]1OS(O)(=O)=O LNUFLCYMSVYYNW-ZPJMAFJPSA-N 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 229940125810 compound 20 Drugs 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- LSXDOTMGLUJQCM-UHFFFAOYSA-M copper(i) iodide Chemical compound I[Cu] LSXDOTMGLUJQCM-UHFFFAOYSA-M 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- DGJMPUGMZIKDRO-UHFFFAOYSA-N cyanoacetamide Chemical compound NC(=O)CC#N DGJMPUGMZIKDRO-UHFFFAOYSA-N 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- JAXFJECJQZDFJS-XHEPKHHKSA-N gtpl8555 Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@@H]1C(=O)N[C@H](B1O[C@@]2(C)[C@H]3C[C@H](C3(C)C)C[C@H]2O1)CCC1=CC=C(F)C=C1 JAXFJECJQZDFJS-XHEPKHHKSA-N 0.000 description 1
- 231100000086 high toxicity Toxicity 0.000 description 1
- IKDUDTNKRLTJSI-UHFFFAOYSA-N hydrazine monohydrate Substances O.NN IKDUDTNKRLTJSI-UHFFFAOYSA-N 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 238000011403 purification operation Methods 0.000 description 1
- 238000007348 radical reaction Methods 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 239000012070 reactive reagent Substances 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 235000010288 sodium nitrite Nutrition 0.000 description 1
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical class O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
- C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D237/14—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C213/00—Preparation of compounds containing amino and hydroxy, amino and etherified hydroxy or amino and esterified hydroxy groups bound to the same carbon skeleton
- C07C213/02—Preparation of compounds containing amino and hydroxy, amino and etherified hydroxy or amino and esterified hydroxy groups bound to the same carbon skeleton by reactions involving the formation of amino groups from compounds containing hydroxy groups or etherified or esterified hydroxy groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
- C07C217/54—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
- C07C217/56—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by singly-bound oxygen atoms
- C07C217/58—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by singly-bound oxygen atoms with amino groups and the six-membered aromatic ring, or the condensed ring system containing that ring, bound to the same carbon atom of the carbon chain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
本发明涉及一种瑞司美替罗中间体化合物4的制备方法,以化合物3为起始原料,先与化合物23反应得到化合物22,接着和化合物2反应得到化合物21,化合物21经脱保护得到瑞司美替罗关键中间体化合物4。该方法反应条件温和,选择性好,操作简单,收率高,纯度高,便于工业化生产。
Description
技术领域
本发明属于医药化工领域,涉及药物瑞司美替罗关键中间体的制备,以及用于制备该中间体的中间体化合物及制备方法。
背景技术
瑞司美替罗Resmetirom (MGL-3196)是美国生物科技公司马德里加尔(Madrigal)旗下在研的一款甲状腺激素受体β(THR-β)激动剂,作为NASH领域首个成功的三期临床药物,用于治疗非酒精性脂肪性肝病(NAFLD)和非酒精性脂肪性肝炎(NASH)患者达到主要终点和关键次要终点。2023年4月,瑞司美替罗被美国FDA授予治疗伴肝纤维化的NASH成人突破性疗法认定。2023年9月,美国FDA授予其优先审评权利,预计2024年上半年完成其新药上市申请(NDA)审查。若其成功上市,将具有极为广阔的市场前景。
瑞司美替罗的化学名为:2-(3,5-二氯-4-((5-异丙基-6-氧代-1,6-二氢哒嗪-3-基)氧基)苯基)-3,5-二氧-2,3,4,5-四氢-1,2,4-三嗪-6-甲腈,结构式如下 :
目前报道的瑞司美替罗的合成方法非常有限,霍夫曼-拉罗齐有限公司在瑞司美替罗化合物专利CN101228135B中公开了一种合成方法,该方法以3,6-二氯哒嗪1为起始原料,通过一步自由基反应生成异丙基化产物2,然后在碘化亚铜催化下化合物2与化合物3进行偶联得到中间体4,中间体4在醋酸/醋酸钠以及氢氧化钠条件下水解得到中间体5,中间体5在亚硝酸钠作用下重氮化并与化合物7偶联得到中间体8,中间体8最后在醋酸/醋酸钠条件下反应得到最终产物瑞司美替罗。路线如下:
该路线的主要问题在于化合物2与化合物3的偶联过程反应选择性非常差,会产生大量异构体杂质,难以清除,纯化困难,中间体4需要进行柱层析进行纯化,这严重限制了该方法的工业化应用。
马德里加尔制药公司的专利CN105008335B报导了另一种合成方法。该方法以3,6-二氯哒嗪1为起始原料,与化合物3进行偶联得到化合物10,然后对化合物10的氨基进行保护,随后经醋酸/醋酸钠条件下水解得到化合物11,接着使用异丙烯基格氏试剂与化合物11加成并在氢氧化钾条件下异构化得到中间体5。
同时该专利中还描述了另一种从化合物11到化合物5的途径:
化合物11与异丙基格氏试剂反应得到13后,通过液溴氧化得到14,然后在氢氧化钠溶液中消除得到化合物5。
以上两种方式虽然能够解决异丙基化步骤的选择性问题,但是使用活性比较高的格氏试剂以及高毒性的液溴,使得整个工艺的成本提高,危险性明显上升。
马德里加尔制药公司的专利CN116406356A中描述了一种通过不同的连接方式来合成化合物5的方法:
化合物15与16在碱的作用下偶联得到化合物17,然后在还原剂的作用下得到化合物5。该方法的问题在于:一方面,化合物15与16的偶联产率较低,且化学选择性难以保证,仍然需要通过柱色谱纯化的方式得到化合物17;另一方面,起始原料化合物15并非商业化试剂,限制了该方法的推广应用。
杭州科巢的专利CN116768802A报导了一种方法:
以3-异丙基呋喃-2,5-二酮化合物18为起始原料,先与水合肼反应得到4-异丙基-1,2-二氢哒嗪-3,6-二酮化合物15,接着氯化得到3,6-二氯-4-异丙基哒嗪化合物2,随后水解得到6-氯-4-异丙基二氢哒嗪n-3(4H)-酮化合物19,再与4-氨基-2,6-二氯苯酚化合物3缩合得到瑞司美替罗关键中间体6-(4-氨基-2 ,6-二氯苯基)-4-异丙基哒嗪-3(2H)-酮化合物5,化合物5经亚硝化后与氰基乙酰胺缩合得到中间体化合物20,最后环合得到目标产物瑞司美替罗9。但是化合物2水解制备化合物19过程中,难以控制水解选择性。
深圳微芯生物科技的专利CN111909137A中报道了一种通过化合物2与3直接偶联得到到化合物4。该该方法的问题在于:化合物2与化合物3偶联选择性较差,仍需通过柱色谱纯化的方式得到化合物4。
综上所述,瑞司美替罗的合成工艺目前面临的问题主要在于偶联过程的选择性较差导致的反应杂质多、中间体纯化困难、反应收率低;CN105008335B的方法则因为高活性试剂的使用而增加了生产过程中的安全风险;瑞司美替罗关键中间体化合物4的合成工艺同样面临偶联过程的选择性较差导致的反应杂质多、中间体纯化困难、反应收率低等问题。所以仍然需要开发新的方法来提高偶联反应选择性,抑制副产物生成,简化中间体纯化操作,降低生产成本。
发明内容
本发明的目的在于对瑞司美替罗关键中间体化合物4的合成进行了改进,提供了一种较为简单的,收率高,产品纯度高,适合工业化生产的合成方法。
为实现上述发明目的,本发明提供了以下技术方案。
本发明提供了一种化合物4的制备方法,其包括如下步骤:
1)化合物22与化合物2在碱性化合物存在条件下反应得到化合物21;
2)化合物21在脱保护试剂存在条件下,经脱保护得到化合物4,
。
本发明的一些实施方案中,步骤1)中,碱性化合物选自:碳酸铯,碳酸钾,氢氧化钾,氢氧化钠,氢氧化铯,叔丁醇钾,叔丁醇钠,正丁基锂,六甲基二硅基氨基锂中的一种或者多种,优选氢氧化钠。
在一些实施方案中,步骤1)中,进一步包含反应溶剂,反应溶剂选自N ,N-二甲基甲酰胺、N ,N-二甲基乙酰胺、N-甲基吡咯烷酮、二甲基亚砜、四氢呋喃、2-甲基四氢呋喃、甲苯、乙腈或水的一种或者多种,优选二甲基亚砜。
在一些实施方案中,步骤2)中,脱保护试剂选自:二氯二氰基苯醌,硝酸铈铵,过氧化氢,叔丁基过氧化氢,三氯化铁,三氟乙酸的一种或者多种,优选三氯化铁。
在一些实施方案中,步骤2)中,进一步包含反应溶剂,反应溶剂选自二氯甲烷、N ,N-二甲基甲酰胺、N ,N-二甲基乙酰胺、N-甲基吡咯烷酮、乙酸乙酯、乙酸异丙酯、四氢呋喃、2-甲基四氢呋喃、甲苯、甲基叔丁基醚或乙腈的一种或者多种,优选二氯甲烷。
在一些实施方案中,步骤2)中,脱保护反应在活性炭存在条件下进行。
进一步地,在本申请的部分实施方案中,本申请还提供了一种化合物22的制备方法,包括如下步骤:化合物3与化合物23缩合反应、再在还原剂的作用下还原得到化合物22,
。
在一些实施方案中,进一步包含吸水剂,吸水剂为无水硫酸镁或无水硫酸钠,优选无水硫酸镁。
在一些实施方案中,上述反应的还原剂选自硼氢化钠,醋酸硼氢化钠,氰基硼氢化钠,优选硼氢化钠。
在一些实施方案中,进一步包含反应溶剂,反应溶剂选自二氯甲烷、甲醇、乙醇、异丙醇、正丁醇、四氢呋喃、2-甲基四氢呋喃、甲苯的一种或多种,优选甲醇或乙醇。
在一些实施方案中,上述反应的反应温度为-20~70℃,优选0~50℃。
更具体地,本发明提供的瑞司美替罗中间体的制备方法采取以下的技术方案:
一种瑞司美替罗关键中间体的制备方法,以4-氨基-2,6-二氯苯酚化合物3为起始原料,先与4-甲氧基苯甲醛反应得到2,6-二氯-4-((4-甲氧基苄基)氨基)苯酚化合物22,接着和3,6-二氯-4-异丙基哒嗪化合物2反应得到3,5-二氯-4-((6-氯-5-异丙基哒嗪-3-基)氧基)-N-(4-甲氧基苄基)苯胺化合物21,最后化合物21经脱保护得到3,5-二氯-4-((6-氯-5-异丙基哒嗪-3-基)氧基)苯胺化合物4。
本发明的有益效果在于:本发明的制备方法,通过对化合物3引入对甲氧基苄基保护基后再与化合物2反应,改善了反应的区域选择性,一方面大大降低了异构体杂质的含量,使得产物纯度大幅提高;另一方面避免了格氏试剂的使用,使得整个过程的操作过程简化,避免了过柱层析纯化,更加适合工业化生产。
具体实施方式
以下实施例用于进一步说明和理解本发明的精神实质,但不以任何方式限制本发明的保护范围。
实施例1
三口烧瓶中加入化合物3(50.00g, 0.28mol)加入甲醇(100mL),加入化合物23(42.00g, 0.31mol),无水硫酸镁(25g),设置温度50℃搅拌1小时。降低温度至0℃,加入硼氢化钠(15.90g, 0.42mol),搅拌30分钟,加入饱和氯化铵溶液(150mL),加入乙酸乙酯(150mL)萃取,分液,收集有机相,用饱和食盐水(100mL)洗涤,有机相减压浓缩干得到化合物22(79.56g, 收率:95%, HPLC纯度:97%)。
1H NMR (600 MHz, Chloroform-d) δ 7.22 (d, J = 8.4 Hz, 2H), 6.86 (d, J = 8.4 Hz, 2H), 6.52 (s, 2H), 4.11 (s, 2H), 3.78 (s, 3H);13C NMR (151 MHz,Chloroform-d) δ 159.1, 142.4, 139.8, 130.6, 128.8, 121.7, 114.2, 112.8, 55.3,48.2;MS(ESI)m/z = 298.0 [M+H]+。
实施例2
三口瓶中加入化合物2(20.00g, 0.10mol)与化合物22(35.89g, 0.12mol),加入二甲基亚砜(200mL),氢氧化钠(6.00g, 0.15mol),升温至70℃搅拌15小时。降温至室温后,缓慢滴加纯化水,过滤,用纯化水洗涤,干燥得化合物21(42.66g, 收率:90%, HPLC纯度:98%)。
1H NMR (600 MHz, Chloroform-d) δ 7.24 (d, J = 8.4 Hz, 2H), 7.15 (s,1H), 6.86 (d, J = 8.4 Hz, 2H), 6.56 (s, 2H), 4.43 (t, J = 5.4 Hz, 1H), 4.17(d, J = 5.4 Hz, 2H), 3.79 (s, 3H), 3.24 (hept, J = 6.6 Hz, 1H), 1.32 (d, J =6.6 Hz, 6H);13C NMR (151 MHz, Chloroform-d) δ 164.5, 159.0, 153.2, 151.0,146.9, 136.2, 130.2, 128.9, 128.7, 115.2, 114.2, 112.3, 55.3, 47.6, 30.3,21.4;MS(ESI)m/z = 452.1 [M+H]+。
实施例3
三口瓶中加入化合物21(20.00g, 44.17mmol),二氯甲烷(400mL),三氯化铁(28.62g, 176.45mmol),25℃搅拌6小时,过滤,滤液用饱和亚硫酸氢钠溶液洗涤,分液,收集有机相,浓缩,加入甲醇溶解,滴加纯化水后析晶,过滤,干燥得到化合物4(12.49g, 收率:85%,HPLC纯度:93%)。
1H NMR (600 MHz, Chloroform-d) δ 7.17 (s, 1H), 6.61 (s, 2H), 3.94 (s,2H), 3.25 (hept, J = 6.6 Hz, 1H), 1.33 (d, J = 6.6 Hz, 6H);13C NMR (151 MHz,CDCl3) δ 164.4, 153.4, 151.2, 145.8, 136.9, 128.8, 115.3, 114.7, 30.3, 21.4;MS(ESI)m/z = 332.0 [M+H]+。
实施例4
三口瓶中加入化合物21(10.00g, 22.09mmol),二氯甲烷(200mL),三氯化铁(14.31g, 88.36mmol),活性炭(10.00g),25℃搅拌6小时,过滤,滤液用饱和亚硫酸氢钠溶液洗涤,分液,收集有机相,浓缩,加入甲醇溶解,滴加纯化水后析晶,过滤,干燥得化合物4(6.10g, 收率:83%,HPLC纯度:98%)。
对比例1:
重复专利CN111909137A中化合物4的合成:
将3,6-二氯-4-异丙基哒嗪(化合物2)(2.00g, 10.47mmol),2,6-二氯-4-氨基苯酚(化合物3)(2.05g,11.52mmol),碳酸铯(6.82g, 20.94mmol)加入到N,N-二甲基甲酰胺(10mL)中,对体系进行氮气置换后90℃反应6小时,加入纯化水稀释后,用乙酸乙酯萃取,合并有机相并收集,用无水硫酸钠干燥,过滤,减压浓缩除去溶剂,得到化合物4粗品(3.56g),HPLC纯度:58.68%。通过柱色谱纯化(乙酸乙酯/石油醚=1/2),得到化合物4(2.36g,收率:68%),HPLC纯度:82.03%。
对比例2:
重复专利CN111909137A中化合物4的合成,但是不使用柱色谱提纯,尝试重结晶提纯:
将3,6-二氯-4-异丙基哒嗪(化合物2)(2.00g, 10.47mmol),2,6-二氯-4-氨基苯酚(化合物3)(2.05g,11.52mmol),碳酸铯(6.82g, 20.94mmol)加入到N,N-二甲基甲酰胺(10mL)中,对体系进行氮气置换后90℃反应6小时,加入纯化水稀释后,用乙酸乙酯萃取,合并有机相并收集,用无水硫酸钠干燥,过滤,减压浓缩除去溶剂,得到化合物4粗品(3.52g),HPLC纯度:58.82%,将粗品溶解于甲醇中,滴加纯化水,冰水浴降温,无固体析出。
Claims (14)
1.一种瑞司美替罗中间体化合物4的制备方法,其包括以下步骤:
1)化合物22与化合物2在碱性化合物存在条件下反应得到化合物21;
,
2)化合物21在脱保护试剂存在下,经脱保护得到化合物4,
。
2.根据权利要求1所述的制备方法,步骤1)中,所述碱性化合物选自:碳酸铯,碳酸钾,氢氧化钾,氢氧化钠,氢氧化铯,叔丁醇钾,叔丁醇钠,正丁基锂,六甲基二硅基氨基锂中的一种或者多种,优选氢氧化钠。
3. 根据权利要求1所述的制备方法,步骤1)中,进一步包含反应溶剂,所述反应溶剂选自N ,N-二甲基甲酰胺、N ,N-二甲基乙酰胺、N-甲基吡咯烷酮、二甲基亚砜、四氢呋喃、2-甲基四氢呋喃、甲苯、乙腈或水的一种或者多种,优选二甲基亚砜。
4.根据权利要求1所述的制备方法,步骤2)中,所述脱保护试剂选自:二氯二氰基苯醌,硝酸铈铵,过氧化氢,叔丁基过氧化氢,三氯化铁,三氟乙酸的一种或者多种,优选三氯化铁。
5. 根据权利要求1所述的制备方法,步骤2中,进一步包含反应溶剂,所述反应溶剂选自二氯甲烷、N ,N-二甲基甲酰胺、N ,N-二甲基乙酰胺、N-甲基吡咯烷酮、乙酸乙酯、乙酸异丙酯、四氢呋喃、2-甲基四氢呋喃、甲苯、甲基叔丁基醚或乙腈的一种或者多种,优选二氯甲烷。
6.根据权利要求1所述的制备方法,步骤2)中,脱保护反应在活性炭存在下进行。
7.根据权利要求1~6任一所述的制备方法,所述化合物22是通过化合物3与化合物23缩合反应、再在还原剂作用下还原得到,
。
8.根据权利要求7所述的制备方法,进一步包含吸水剂,所述吸水剂为无水硫酸镁或无水硫酸钠,优选无水硫酸镁。
9.根据权利要求7所述的制备方法,所述还原剂选自硼氢化钠,醋酸硼氢化钠,氰基硼氢化钠,优选硼氢化钠。
10.根据权利要求7所述的制备方法,进一步包含反应溶剂,所述反应溶剂选自二氯甲烷、甲醇、乙醇、异丙醇、正丁醇、四氢呋喃、2-甲基四氢呋喃、甲苯的一种或多种,优选甲醇或乙醇。
11.根据权利要求7所述的制备方法,反应温度为-20~70℃,优选0~50℃。
12.一种如下式所示的中间体化合物21:
。
13.一种如下式所示的中间体化合物22:
。
14.权利要求12~13任一所述中间体化合物在制备瑞司美替罗中的用途。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202410111330.1A CN117964557A (zh) | 2024-01-26 | 2024-01-26 | 一种瑞司美替罗中间体的制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202410111330.1A CN117964557A (zh) | 2024-01-26 | 2024-01-26 | 一种瑞司美替罗中间体的制备方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN117964557A true CN117964557A (zh) | 2024-05-03 |
Family
ID=90850659
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202410111330.1A Pending CN117964557A (zh) | 2024-01-26 | 2024-01-26 | 一种瑞司美替罗中间体的制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN117964557A (zh) |
-
2024
- 2024-01-26 CN CN202410111330.1A patent/CN117964557A/zh active Pending
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP3712130B1 (en) | Method for synthesis of roxadustat and intermediate compounds thereof | |
EP1713801B1 (en) | Process for preparation of 1-(2s,3s)-2-benzhydr yl-n-(5-tert-butyl-2-methoxybenzyl)quinuclidin-3-amine | |
CN112047888B (zh) | 一种合成恩杂鲁胺的方法 | |
EP2133322A1 (en) | Process of preparing derivatives of 1-(2-halobiphenyl-4-yl)-cyclopropanecarboxylic acid | |
JP2011521001A (ja) | エゼチミブおよびそれを含む組成物の調製方法 | |
JPH0261476B2 (zh) | ||
JP4031203B2 (ja) | (1r,2s,4r)−(−)−2−[(2’−{n,n−ジメチルアミノ}−エトキシ)]−2−[フェニル]−1,7,7−トリ−[メチル]−ビシクロ[2.2.1]ヘプタン及びその薬学上許容される酸付加塩の製法 | |
CN117964557A (zh) | 一种瑞司美替罗中间体的制备方法 | |
US20230128975A1 (en) | Process for the preparation of bromodomain inhibitor | |
CN111100042B (zh) | 一种2-甲氧基-5-磺酰胺基苯甲酸的制备方法 | |
JP3446899B2 (ja) | ハロピリジル−アザビシクロヘプタン誘導体の製造法および中間体 | |
JP2835413B2 (ja) | フェノチアジン誘導体およびその製造方法 | |
JP2894366B2 (ja) | デアセチルコルヒチンの製造方法 | |
EP1926709A1 (en) | Process for the preparation of chiral 3-hydroxy pyrrolidine compound and derivatives thereof having high optical purity | |
CN114031535B (zh) | 一种改进的盐酸维纳卡兰的合成方法 | |
CN111072543B (zh) | 一种(3r,4s)-4-乙基吡咯烷-3-羧酸类化合物的制备方法及其应用 | |
JPH05140168A (ja) | インドロカルバゾール誘導体及び該化合物を有効成分とする抗腫瘍剤 | |
CN107459501B (zh) | 一种奥格列汀的手性中间体的制备方法 | |
US7557237B2 (en) | Process for the synthesis of 3-(3-fluoro-4-hydroxyphenyl)-7-hydroxynaphthonitrile | |
JP2024526159A (ja) | Cyp11a1阻害薬及びその中間体を調製する方法 | |
JPH05331140A (ja) | 2−アザビシクロ[2.2.1ヘプト−5−エン−3−オンの製造方法 | |
CN118388413A (zh) | 一种制备6-(4-氨基-2,6-二氯苯氧基)-4-异丙基哒嗪-3(2h)-酮的方法 | |
JP2003137835A (ja) | (r)−3−ヒドロキシ−3−(2−フェニルエチル)ヘキサン酸の製造方法 | |
JPS5993059A (ja) | シトシン類の製法 | |
CN103443095A (zh) | 制备齐多夫定及其中间体的方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |